BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 21270174)

  • 1. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.
    Birkeland KI; Home PD; Wendisch U; Ratner RE; Johansen T; Endahl LA; Lyby K; Jendle JH; Roberts AP; DeVries JH; Meneghini LF
    Diabetes Care; 2011 Mar; 34(3):661-5. PubMed ID: 21270174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.
    Heise T; Tack CJ; Cuddihy R; Davidson J; Gouet D; Liebl A; Romero E; Mersebach H; Dykiel P; Jorde R
    Diabetes Care; 2011 Mar; 34(3):669-74. PubMed ID: 21285389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
    Gough SC; Bhargava A; Jain R; Mersebach H; Rasmussen S; Bergenstal RM
    Diabetes Care; 2013 Sep; 36(9):2536-42. PubMed ID: 23715753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.
    Mathieu C; Hollander P; Miranda-Palma B; Cooper J; Franek E; Russell-Jones D; Larsen J; Tamer SC; Bain SC;
    J Clin Endocrinol Metab; 2013 Mar; 98(3):1154-62. PubMed ID: 23393185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
    Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes.
    Urakami T; Mine Y; Aoki M; Okuno M; Suzuki J
    Endocr J; 2017 Feb; 64(2):133-140. PubMed ID: 27746408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials.
    Rodbard HW; Gough S; Lane W; Korsholm L; Bretler DM; Handelsman Y
    Endocr Pract; 2014 Apr; 20(4):285-92. PubMed ID: 24246344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
    Pan C; Gross JL; Yang W; Lv X; Sun L; Hansen CT; Xu H; Wagner R
    Drugs R D; 2016 Jun; 16(2):239-49. PubMed ID: 27098525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
    Meneghini L; Atkin SL; Gough SC; Raz I; Blonde L; Shestakova M; Bain S; Johansen T; Begtrup K; Birkeland KI;
    Diabetes Care; 2013 Apr; 36(4):858-64. PubMed ID: 23340894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.
    Zinman B; DeVries JH; Bode B; Russell-Jones D; Leiter LA; Moses A; Johansen T; Ratner R;
    Lancet Diabetes Endocrinol; 2013 Oct; 1(2):123-31. PubMed ID: 24622318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study.
    Nakamura T; Sakaguchi K; So A; Nakajima S; Takabe M; Komada H; Okuno Y; Hirota Y; Nakamura T; Iida K; Kajikawa M; Nagata M; Ogawa W; Seino S
    Diabetologia; 2015 Sep; 58(9):2013-9. PubMed ID: 26044206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
    Ratner RE; Gough SC; Mathieu C; Del Prato S; Bode B; Mersebach H; Endahl L; Zinman B
    Diabetes Obes Metab; 2013 Feb; 15(2):175-84. PubMed ID: 23130654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study.
    Koehler G; Heller S; Korsatko S; Roepstorff C; Rasmussen S; Haahr H; Pieber TR
    Diabetologia; 2014 Jan; 57(1):40-9. PubMed ID: 24057153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.
    Davies MJ; Gross JL; Ono Y; Sasaki T; Bantwal G; Gall MA; Niemeyer M; Seino H;
    Diabetes Obes Metab; 2014 Oct; 16(10):922-30. PubMed ID: 24702700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial.
    Onishi Y; Ono Y; Rabøl R; Endahl L; Nakamura S
    Diabetes Obes Metab; 2013 Sep; 15(9):826-32. PubMed ID: 23557077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS.
    Einhorn D; Handelsman Y; Bode BW; Endahl LA; Mersebach H; King AB
    Endocr Pract; 2015 Aug; 21(8):917-26. PubMed ID: 26121451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial].
    Mu YM; Guo LX; Li L; Li YM; Xu XJ; Li QM; Xu MT; Zhu LY; Yuan GY; Liu Y; Xu C; Wang ZJ; Shen FX; Luo Y; Liu JY; Li QF; Wang WH; Lai XY; Xu HF; Pan CY
    Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):660-666. PubMed ID: 28870034
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial.
    Aso Y; Suzuki K; Chiba Y; Sato M; Fujita N; Takada Y; Murano S; Kuroda H
    Diabetes Res Clin Pract; 2017 Aug; 130():237-243. PubMed ID: 28651211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
    Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL
    Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.
    Onishi Y; Iwamoto Y; Yoo SJ; Clauson P; Tamer SC; Park S
    J Diabetes Investig; 2013 Nov; 4(6):605-12. PubMed ID: 24843715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.